Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel R. Faga
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Beta
- 3.37
- Country
- US
Financials
TRAX has only 3 quarterly periods on file — the charts below show the full history available.
Net Income
$-33.37MEBITDA
$-34.73MFree Cash Flow
$-31.94MEPS (diluted)
$-0.94Shares Outstanding (diluted)
35.39M+1.8%Operating Expenses
$34.73MCash & Debt
$168.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-166.09M | $0.00 |
| 2024 | $0.00 | $-163.71M | $0.00 |
| 2023 | $0.00 | $-106.15M | $-3.05 |
Valuation
TRAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·40d ago·Positive
First Tracks Biotherapeutics Announces Participation in September Investor Conferences SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
View source ↗ - Newsbenzinga.com·54d ago·Negative
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
View source ↗
Earnings
Typical surprise -18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.95 vs $-0.80miss
Estimates and results for TRAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRAX officers and directors.
No open-market trades in the recent filings. All 2 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
2 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TRAX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.